KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, acquires, licenses, and markets technologically distinguished branded and multisource products.

We apply this technology to our three wholly owned subsidiaries, Ther-Rx Corporation, ETHEX Corporation, and Particle Dynamics, Inc., which market technologically differentiated products to the brand and multisource marketplaces and value-added, specialty ingredient products to the pharmaceutical, personal care, food, and nutritional markets.

Drug Delivery Research and Development
Today, our research and development activities include the development of new and next-generation drug delivery technologies and the formulation of proprietary brand name and multisource products.

KV's approach to new product development through application of delivery technology to known drugs is faster and far less risky than research of new molecular entities. Our drug delivery depth and breadth allows us to have 15 technological approaches in various stages of commercialization and not wait in an academic or theoretical mode.

These technologies fall within four principal areas: 1) SITE RELEASE® (bioadhesive), 2) Tastemasking, 3) Quick-Dissolving Tablets, and 4) Oral Extended/Delayed Release.

	KV's success is partly attributed to its development of breakthrough technologies in four principal areas:
	SITE RELEASE® KV's SITE RELEASE® family of drug delivery systems offers a creative, unique approach to drug delivery that relies on bioadhesion to wet and dry living tissues, coupled with controlled release of the drug agent. Products incorporating KV's SITE RELEASE® technologies are designed to adhere to wet and dry living tissues yet are minimally affected by the presence of moisture. Each of the SITE RELEASE® technologies is individually tailored to optimize drug delivery for oral, topical, or a specific orificial use.
	Tastemasking Our tastemasking technologies improve the taste of unpleasant drugs. This technology provides better-tasting liquid (FlavorTech®); chewable, quick-dissolving, or effervescent tablets and ingredients (MicroMask™); and dry powder formulations (LIQUETTE™); even for extremely bitter-tasting drugs.
	Quick-Dissolving Tablets KV is developing a quick-dissolving tablet technology that exhibits the ability to tastemask, yet dissolves in the mouth in a matter of seconds. Most other quick-dissolving technologies offer either quickness at the expense of poor tastemasking or excellent tastemasking at the expense of slower disintegration of the tablet in the mouth.
	Oral Extended/Delayed Release Our oral extended/delayed release technologies can be tailored to the desired release profile for a given drug. The release profile is dependent on many parameters, such as drug solubility, protein-binding, and site of absorption. Our oral extended/delayed release technologies include KV/24® (for once daily dosing) and METER RELEASE® (for twice daily dosing).

Added to our expertise in drug delivery technologies is our commitment to have in place state-of-the-art laboratory and manufacturing capabilities. Today, KV has over 1,000,000 square feet of predominantly owned facility space. We have three shift operations in place that are able to produce in commercial quantities products developed using our drug delivery technologies.

For more information, please visit www.kvpharmaceutical.com.